Primary prophylaxis of invasive fungal infections in patients with haematological malignancies: 2017 update of the recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society for Haematology and Medical Oncology (DGHO)
AbstractImmunocompromised patients are at high risk of invasive fungal infections (IFI), in particular those with haematological malignancies undergoing remission-induction chemotherapy for acute myeloid leukaemia (AML) or myelodysplastic syndrome (MDS) and recipients of allogeneic haematopoietic stem cell transplants (HSCT). Despite the development of new treatment options in the past decades, IFI remains a concern due to substantial morbidity and mortality in these patient populations. In addition, the increasing use of new immune modulating drugs in cancer therapy has opened an entirely new spectrum of at risk periods. Since the last edition of antifungal prophylaxis recommendations of the German Society for Haematology and Medical Oncology in 2014, seven clinical trials regarding antifungal prophylaxis in patients with haematological malignancies have been published, comprising 1227 patients. This update assesses the impact of this additional evidence and effective revisions. Our key recommendations are the following: prophylaxis should be performed with posaconazole delayed release tablets during remission induction chemotherapy for AML and MDS (AI). Posaconazole iv can be used when the oral route is contraindicated or not feasible. Intravenous liposomal amphotericin B did not significantly decrease IFI rates in acute lymphoblastic leukaemia (ALL) patients during induction chemotherapy, and there is poor evidence to recommend it for prophylaxis in these patients (CI). De...
Journal Name: Drug Metabolism and Personalized Therapy Issue: Ahead of print
Conclusions The bEnd3 cell line represents a useful in vitro tool for studying BBB characteristics and drug transport mechanisms at the BBB. PMID: 29683403 [PubMed - as supplied by publisher]
In KEYNOTE-189, a pembrolizumab/chemo combination yielded OS and PFS benefits in patients with advanced NSCLC.
CRISPR/Cas9 genome editing technology significantly accelerated herpes simplex virus research, Published online: 25 April 2018; doi:10.1038/s41417-018-0016-3CRISPR/Cas9 genome editing technology significantly accelerated herpes simplex virus research
Date: Wednesday, 05 23, 2018; Speaker: Matthew Gamble, Ph.D., Associate Professor, Albert Einstein College of Medicine; Building: Building 41; C507/C509
Albert Thompson was initially denied NHS treatment for prostate cancer until he proved his status.
Conclusion: Collectively, our results demonstrate that AFSCs may be a promising therapeutic treatment for ameliorating diabetes and the development of diabetic nephropathy and that the overexpression of SIRT3 in AFSCs may further increase the efficiency of stem cell-based therapy.Cell Physiol Biochem 2018;46:1508 –1524
Conclusions: These results indicate that ENO2 may be a biological marker for monitoring chemotherapeutic efficacy and relapse in ALL. ENO2 may provide a potential therapeutic strategy for ALL.Cell Physiol Biochem 2018;46:1525 –1535
As 4-year-0ld Elianna Grace sat in the back seat of the SUV, battling her second fever in three days, her mom flashed back to the coughing and vomiting fit the preschooler had the previous weekend — and to a niggling fear about the girl's sudden illness. Elianna had spent April 14 playing in her grandparents' […]Related:FDA cracks down on sales of Juul, other e-cigarettes to youthsInside the secret U.S. stockpile meant to save us all in a bioterror attackVeteran receives penis and scrotum transplant in surgery doctors say is a medical first
In conclusion, current literature indicated that APC therapy was an effective and safe strategy for hemorrhagic CRP, and large-scale prospective studies are needed to warrant our study. PMID: 29681929 [PubMed]
More News: Abelcet | Acute Leukemia | Acute Lymphoblastic Leukemia | Acute Myeloid Leukemia | Cancer | Cancer & Oncology | Cancer Therapy | Chemotherapy | Clinical Trials | Fungal Infections | Germany Health | Hematology | Infectious Diseases | Leukemia | Myelodysplastic Syndrome | Oral Cancer | Stem Cell Therapy | Stem Cells | Transplants